References
- 1. THIELE M., KJAERGAARD M., THIELSEN P., KRAG A. Contemporary use of elastography in liver fibrosis and portal hypertension. Clin Physiol Funct Imaging 2017; 37:235-42.
- 2. GRUGUREVIC I., BOZIN T., MADIR A. Hepatitis C is now curable, but what happens with cirrhosis and portal hypertension afterwards? Clin Exp Hepatol 2017; 3:181-6.
- 3. DOLMAZASHVILI E., ABUTIDZE A., CHKHARTISHVILI N., KARCHAVA M., SHARVADZE L., TSERTSVADZE T. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience. Eur J Gastroenterol Hepatol 2017; 29:1223-30.
- 4. TSOCHATZIS E.A., GERMANI G., HALL A., MANUOUSOU P., DHILLON A.P., BURROUGHS A.K. Noninvasive assessment of liver fibrosis: The need for better validation. Hepatology 2011; 53:1781-2.
- 5. SINGH S.,MUIR A.J., DIETERICH D.T., FALCK-YTTER Y.T. American gastroenterological association institute technical review on the role of elastography in chronic liver diseases. Gastroenterology 2017; 152:1544-77.
- 6. SPOREA I., BOTA S., GRĂDINARU-TAŞCĂU O., ŞIRLI R., POPESCU A. Comparative study between two point Shear Wave Elastographic techniques: Acoustic Radiation Force Impulse (ARFI) elastography and ElastPQ. Med Ultrason 2014; 16:309-14.
- 7. GRGUREVIC I., BOKUN T., BOZIN T., MATIC V., HABERLE S., SPOREA I. Non-invasive diagnosis of portal hypertension in cirrhosis using ultrasound based elastography. Med Ultrason 2017; 19:310-7.
- 8. EUROPEAN ASDSOCIATION FOR THE STUDY OF THE LIVER, ASOCIATIÓN LATINOAMERICANA PARA EL ESTUDIO DEL HIGADO. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 63:237-64.
- 9. CASTERA L., FORNS X., ALBERTI A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48:835-47.
- 10. ROULOT D., CZERNICHOW S., LE CLESIAU H., COSTES J.L., VERGNAUD A.C., BEAUGRAND M. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol 2008; 48:606-13.
- 11. KIM S.U., CHOI G.H., HAN W.K., KIM B.K., PARK J.Y., KIM DO Y., et al. What are ‘true normal’ liver stiffness values using FibroScan?: a prospective study in healthy living liver and kidney donors in South Korea. Liver Int 2010;30:268-74.
- 12. COLOMBO S., BELLOLI L., ZACCANELLI M., BADIA E., JAMOLETTI C., BUONOCORE M., et al. Normal liver stiffness and its determinants in healthy blood donors. Dig Liver Dis 2011;43:231-36.
- 13. DAS K., SARKAR R., AHMED S.M., MRIDHA A.R., MUKHERJEE P.S., DHALI G.K., et al. “Normal” liver stiffness measure (LSM) values are higher in both lean and obese individuals: a population-based study from a developing country. Hepatology 2012;55:584-93.
- 14. DIETRICH C.F., BAMBER J., BERZIGOTTI A., BOTA S., CANTISANI V., CASTERA L., et al. EFSUMB guidelines and recommendations on the clinical use of liver ultrasound elastography, update 2017 (long version). Ultraschall Med 2017;38:e16-e47.
- 15. MENDES L.C., FERREIRA P.A., MIOTTO N., ZANAGA L., GONÇALES E.S.L., PEDRO M.N., et al. Elastogram quality assessment score in vibration-controlled transient elastography: Diagnostic performance compared to digital morphometric analysis of liver biopsy in chronic hepatitis C. J Viral Hepat 2018;25:335-43.
- 16. CONTI F., SERRA C., VUKOTIC R., FIORINI E., FELICANI C., MAZZOTTA E., et al. Accuracy of elastography point quantification and steatosis influence on assessing liver fibrosis in patients with chronic hepatitis C. Liver Int 2017;37:187-95.
- 17. BOTA S, SPOREA I, PECK-RADOSAVLJEVIC M, SIRLI R, TANAKA H, IIJIMA H, et al. The influence of aminotransferase levels on liver stiffness assessed by Acoustic Radiation Force Impulse Elastography: a retrospective multicentre study. Dig Liver Dis 2013;45:762–8.
- 18. TSUKANO N., MIYASE S., SAEKI T., MIZOBE K., IWASHITA H., ARIMA N., et al. Usefulness of Virtual Touch Quantification for staging liver fibrosis in patients with hepatitis C, and the factors affecting liver stiffness measurement failure compared with liver biopsy. Hepatol Res 2018;48:373-82.
- 19. SUMMERS J.A., RADHAKRISHAN M., MORRIS E., CHALKIDOU A., RUA T., PATEL A., et al. Virtual Touch™ quantification to diagnose and monitor liver fibrosis in hepatitis B and hepatitis C: A NICE medical technology guidance. Appl Health Econ Health Policy 2017;15:139-54.
- 20. GHARIB A.M., HAN M.A.T., MEISSNER E.G., KLEINER D.E., ZHAO X., MCLAUGHLIN M., et al. Magnetic resonance elastography shear wave velocity correlates with liver fibrosis and hepatic venous pressure gradient in adults with advanced liver disease. Biomed Res Int 2017;2017:2067-479.
- 21. THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES AND THE INFECTIOUS DISEASES SCOCIETY OF AMERICA. HCV Guidance: recommendations for testing, managing, and treating hepatitis C. www.HCVGuidance.org on August 13, 2018.
- 22. ZIOL M., HANDRA-LUCA A., KETTANEH A., CHIRSTIDIS C., MAL F., KAZEMI F., et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;41:48-54.
- 23. AFDAHAL N.H., BACON B.R., PATEL K., LAWITZ E.J., GORDON S.C., NELSON D.R., et al. Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. Clin Gastroenterol Hepatol 2015;13:772-9.
- 24. CASTERA L., VERGNIOL J., FOUCHER J., LE B.B., CHANTELOUP E., HAASER M., et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-50.
- 25. CASTERA L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 2012;142:1293-302.
- 26. BONDER A., AFDHAL N.H. Utilization of FibroScan in clinical practice. Curr Gastroenterol Rep 2014;16:372.
- 27. NAKAMURA Y., AIKATA H., FUKUHARA T., HONDA F., MORIO K., MORIO R., et al. Liver fibrosis assessment by FibroScan compared with pathological findings of liver resection specimen in hepatitis C infection. Hepatol Res 2017;47:767-72.
- 28. PaARANAGUÁ-VEZOZZO D.C., ANDRADE A., MAZO D.F., NUNES V., GUEDES A.L., RAGAZZO T.G., et al. Concordance of non-invasive mechanical and serum tests for liver fibrosis evaluation in chronic hepatitis C. World J Hepatol 2017;9:436-42.
- 29. DOLMAZASHVILI E., KARCHAVA M., ABUTIDZE A., SHARVADZE L., TSERTSVADZE T. Comparative study of FIB-4 index and transient elastography among patients with chronic hepatitis C virus infection in Georgia. Georgian Med News 2017;264:81-6.
- 30. KJÆRGAARD M., THIELE M., JANSEN C., STÆHR MADSEN B., GÖRTZEN J., STRASSBURG C., et al. High risk of misinterpreting liver and spleen stiffness using 2D shear-wave and transient elastography after a moderate or high calorie meal. PLoS One 2017;12:e0173992.
- 31. DUCANCELLE A., LEROY V., VERGNIOL J., STURM N., LE BAIL B., ZARSKI J.P., et al. A single test combining blood markers and elastography is more accurate than other fibrosis tests in the main causes of chronic liver diseases. J Clin Gastroenterol 2017;51:639-49.
- 32. GANI R.A., HASAN I., SANITYOSO A., LESMANA C.R.A., URNIAWAN J., JASIRWAN C.O.M., et al. Evaluation of Acoustic Radiation Force Impulse (ARFI) for fibrosis staging in chronic liver diseases. Acta Med Indones 2017;49:128-35.
- 33. PISCAGLIA F., SALVATORE V., MULAZZANI L., CANTISANI V., COLECCHIA A.,DI DONATO R., et al. Differences in liver stiffness values obtained with new ultrasound elastography machines and Fibroscan: A comparative study. Dig Liver Dis 2017;49:802-8.
- 34. MARE R., SPOREA I., LUPUŞORU R., ŞIRLI R., POPESCU A., DANILA M., et al. The value of ElastPQ for the evaluation of liver stiffness in patients with B and C chronic hepatopathies. Ultrasonics 2017;77:144-51.
- 35. TSOCHATZIS E.A., GURUSAMY K.S., NTAOULA S., CHOLONGITAS E., DAVIDSON B.R., BURROUGHS A.K. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol 2011;54:650-9.
- 36. MOUSTAFA E.F., MAKHLOUF N., HASSANY S.M., HELMY A., NASR A., OTHMAN M., et al. Non-invasive assessment of liver fibrosis in patients with hepatitis C: Shear wave elastography and colour Doppler velocity profile technique versus liver biopsy. Arab J Gastroenterol 2017;18:6-12.
- 37. GOMEZ-MORENO A.Z., PINEDA-TENOR D., JIMENEZ-SOUSA M.A., SÁNCHEZ-RUANO J.J., ARTAZA-VARASA T., SAURA-MONTALBAN J., et al. Liver stiffness measurement predicts liver-related events in patients with chronic hepatitis C: A retrospective study. PLoS One 2017;12:e0184404.
- 38. BOGLIONE L., CUSATO J., CARITI G., DI PERRI G., D’AVOLIO A. Role of IL28B genotype in the liver stiffness increase in untreated patients with chronic hepatitis C. Infect Genet Evol 2017;53:195-8.
- 39. SCHWABL P., MANDORFER M., STEINER S., SCHEINER B., CHROMY D., HERAC M., et al. Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease. Aliment Pharmacol Ther 2017;45:139-49.
- 40. LENS S., ALVARADO E., MARIÑO Z., LONDOÑO M.C., LLOP E., MARTINEZ J., et al. Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis. Gastroenterology 2017;153:1273-83.e1.
- 41. TAG-ADEEN M., ALSENBESY M., GHWEIL A.A., ABD ELRAZEK M.A.H., ELGOHARY E.A., SALLAM M.M., et al. Liver stiffness measurement and spleen diameter as predictors for the presence of esophageal varices in chronic hepatitis C patients. Medicine (Baltimore) 2017;96:e8621.
- 42. SILVA M.J., BERNARDES C., PINTO J., LOUREIRO R., DUARTE P., MENDES M., et al. Baveno VI recommendation on avoidance of screening endoscopy in cirrhotic patients: Are we there yet? GE Port J Gastroenterol 2017;24:79-83.
- 43. AUGUSTIN S., PONS M., MAURICE J.B., BUREAU C., STEFANESCU H., NEY M., et al. Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease. Hepatology 2017;66:1980-8.
- 44. MARCONI C., BELLAN M., GIARDA P., MINISINI R., FAVRETTO S., BURLONE M.E., et al. Cardiac dysfunction as an early predictor of portal hypertension in chronic hepatitis C. Ann Gastroenterol 2017;30:675-81.
- 45. BELLAN M., SAINAGHI P.P., MINH M.T., MINISINI R., MOLINARI L., BALDRIGHI M., et al. Gas6 as a predictor of esophageal varices in patients affected by hepatitis C virus related-chronic liver disease. Biomark Med 2018;12:27-34.
- 46. CHROMY D., SCHWABL P., BUCSICS T., SCHEINER B., STRASSI R., MAYER F., et al. Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients. Wien Klin Wochenschr 2018;130:105-14.
- 47. CEPEDA J.A., THOMAS D.L., ASTEMBORSKI J., SULKOWSKI M.S., KIRK G.D., MEHTA S.H. Increased mortality among persons with chronic hepatitis C with moderate or severe liver disease: A cohort study. Clin Infect Dis 2017;65:235-43.
- 48. FACCIORUSSO A., DEL PRETE V., TURCO A., BUCCINO R.V., NACCHIERO M.C., MUSCATIELLO N. Long-term liver stiffness assessment in HCV patients undergoing antiviral therapy: Results from a 5-year cohort study. J Gastroenterol Hepatol 2018;33:942-9.
- 49. CHEN YI MEI S.L.G., THOMPSON A.J., CHRISTENSEN B., CUNNINGHAM G., MCDONALD L., et al. Sustained virological response halts fibrosis progression: A long-term follow-up study of people with chronic hepatitis C infection. PLoS One 2017;12:e0185609.
- 50. PONS M., SANTOS B., SIMÓN-TALERO M., VENTURA-COTS M., RIVEIRO-BARCIELA M., ESTEBAN R., et al. Rapid liver and spleen stiffness improvement in compensated advanced chronic liver disease patients treated with oral antivirals. Therap Adv Gastroenterol 2017;10:619-29.
- 51. TACHI Y., HIRAI T., KOJIMA Y., ISHIZU Y., HONDA T., KUZUYA T., et al. Liver stiffness reduction correlates with histological characteristics of hepatitis C patients with sustained virological response. Liver Int 2017;38:59-67.
- 52. CHAN J., GOELA N., ZHENG H., LAMMERT S., AJAYI T., FRICKER Z., et al. Direct-acting antiviral therapy for chronic HCV infection results in liver stiffness regression over 12 months post-treatment. Dig Dis Sci 2018;63:486-92.
- 53. RAMOS H., LINARES P., BADIA E., MARTIN I., GÓMEZ J., ALMOHALLA C., et al. Asociación Castellano Y Leonesa de Hepatología ACyLHE. Interferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world setting. World J Gastrointest Pharmacol Ther 2017;8:137-46.
- 54. ELSHARKAWY A., ALEM S.A., FOUARD R., EL RAZIKY M., EL AKEL W., ABDO M., et al. Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon. J Gastroenterol Hepatol 2017;32:1624-30.
- 55. NEUKAM K., MORANO-AMADO L.E., RIVERO-JUÁREZ A., MACÍAS J., GRANADOS R., ROMERO-PALACIOS A., et al. Grupo de Estudio de Hepatitis Vírica, of the Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica: GEHEP- SEIMC and Grupo de Estudio de Hepatitis Vírica, of the Sociedad Andaluza de Enfermedades Infecciosas y Microbiología Clínica: HEPAVIR/Red de Investigación en SIDA (RIS-HEP07). Liver stiffness predicts the response to direct-acting antiviral-based therapy against chronic hepatitis C in cirrhotic patients. Eur J Clin Microbiol Infect Dis 2017;36:853-61.
- 56. AKUTA N., SEZAKI H., SUZUKI F., KAWAMURA Y., HASAKA T., KOBAYASHI M., et al. Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older. J Med Virol 2017;89:91-8.
- 57. OGASAWARA N., KOBAYASHI M., AKUTA N., KOMINAMI Y., FUJIYAMA S., KAWAMURA Y., et al. Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b. J Med Virol 2017;90:313-9.
- 58. SINGH S., FACCIORUSSO A., LOOMBA R., FALCK-YTTER Y.T. Magnitude and kinetics of decrease in liver stiffness after antiviral therapy in patients with chronic hepatitis C: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2017;16:27-38.e4.
- 59. TAG-ADEEN M., SABRA A.M., AKAZAWA Y., OHNITA K., NAKAO K. Impact ofhepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement. Hepat Med 2017;9:45-53.
- 60. JIMÉNEZ-SOUSA M.Á., GÓMEZ-MORENO A.Z., PINEDA-TENOR D., MEDRANO L.M., SÁNCHEZ-RUANO J.J., FERNÁNDEZ-RODRÍGUEZ A., et al. CXCL9-11polymorphisms are associated with liver fibrosis in patients with chronic hepatitis C: a cross-sectional study. Clin Transl Med 2017;6:26.
- 61. STEINER S., BUCSICS T., SCHWABL P., MANDORFER M., SCHEINER B., AICHELBURG M.C., et al. Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna. Wien Klin Wochenschr 2017;129:517-26.
- 62. SPOREA I., LUPUŞORU R., MARE R., POPESCU A., GHEORGHE L., IACOB S., et al. Dynamics of liver stiffness values by means of transient elastography in patients with HCV liver cirrhosis undergoing interferon free treatment. J Gastrointestin Liver Dis 2017;26:145-50.
- 63. FERRAIOLI G., MAIOCCHI L., LISSANDRIN R., TINELLI C., DE SILVESTRI A., FILICE C. on behalf of the Liver Fibrosis Study Group. Ruling-in and ruling-out significant fibrosis and cirrhosis in patients with chronic hepatitis C using a shear wave measurement method. J Gastrointestin Liver Dis 2017;26:139-43.
- 64. TADA T., KUMADA T., TOYODA H., MIZUNO K., SONE Y., KATAOKA S., et al. Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. J Gastroenterol Hepatol 2017;32:1982-8.
- 65. SUDA T., OKAWA O., MASAOKA R., GYOTOKU Y., TOKUTOMI N., KATAYAMA Y., et al. Shear wave elastography in hepatitis C patients before and after antiviral therapy. World J Hepatol 2017;9:64-8.
- 66. DELLA-GUARDIA B., EVANGELISTA A.S., FELGA G.E., MARINS L.V., SALVALAGGIO P.R., ALMEIDA M.D. Diagnostic accuracy of transient elastography for detecting liver fibrosis after liver transplantation: A specific cut-off value is really needed? Dig Dis Sci 2017;62:264-72.
- 67. KORDA D., LENARD Z.M., GERLEI Z., JAKAB Z., HABOUB-SANDIL A., WAGNER L., et al. Shear-wave elastography for the assessment of liver fibrosis in liver transplant recipients treated for hepatitis C virus recurrence. Eur J Gastroenterol Hepatol 2017;30:27-32.
- 68. MARTINI S., SACCO M., STRONA S., ARESE D., TANDOI F., DELL OLIO D., et al. Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis. Liver Int 2017;37:62-70.
- 69. MAURO E., CRESPO G., MONTIRONI C., LONDOÑO M.C., HERNÁNDEZ-GEA V., RUIZ P., et al. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after SVR in recurrent hepatitis C. Hepatology 2018;67:1683-94.
- 70. BREGENZER A., CONEN A., KNUCKEL J., FRIEDL A., EIGENMANN. F, NÄF M., et al. Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade. Swiss Med Wkly 2017;147:w14544.
- 71. PARISI S.G., BASSO M., MENGOLI C., SCAGGIANTE R., ANDREIS S., FRANZETTI M.M., et al. Liver stiffness is not associated with short- and long-term plasma HIV RNA replication in immunocompetent patients with HIV infection and with HIV/HCV coinfection. Ann Gastroenterol 2017;30:534-1.
- 72. ERMAN A., SATHYA A., NAM A., BIELOECKI J.M., FELD J.J., THEIN H.H., et al. Estimating chronic hepatitis C prognosis using transient elastography-based liver stiffness: A systematic review and meta-analysis. J Viral Hepat 2018;25:502-13.
- 73. BRUNO G., SARACINO A., SCUDELLER L., FABRIZIO C., DELL’ACQUA R., MILANO E., et al. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ? Int J Infect Dis 2017;62:64-71.
- 74. MERCHANTE N., RIVERO-JUÁREZ A., TÉLLEZ F., MERINO D., RÍOS-VILLEGAS M.J., OJEDA-BURGOS G., et al.; Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Liver stiffness predicts variceal bleeding in HIV/HCV-coinfected patients with compensated cirrhosis. AIDS 2017;31:493-500.
- 75. XU H., KONG W., LIU L., CHI X., WANG X., WU R., et al. Accuracy of M2BPGi, compared with Fibro Scan®, in analysis of liver fibrosis in patients with hepatitis C. BMC Gastroenterol 2017;17:62.
- 76. SOTO M., SAMPIETRO-COLOM L., LASALVIA L., MIRA A., JIMÉNEZ W., NAVASA M. Cost-effectiveness of enhanced liver fibrosis test to assess liver fibrosis in chronic hepatitis C virus and alcoholic liver disease patients. World J Gastroenterol 2017;23:3163-73.
- 77. BACHOFNER J.A., VALLI P.V., KRÓGER A., BERGAMIN I., KÜNZLER P., BASERGA A., et al. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. Liver Int 2017;37:369-76.